0001161697-19-000538.txt : 20191206 0001161697-19-000538.hdr.sgml : 20191206 20191206165222 ACCESSION NUMBER: 0001161697-19-000538 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191204 FILED AS OF DATE: 20191206 DATE AS OF CHANGE: 20191206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: INGENITO GARY CENTRAL INDEX KEY: 0001279473 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 191273629 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 1500 CITY: CORAL GABLES STATE: FL ZIP: 33134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 1250 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 1250 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 4 1 form4.xml FORM 4 FOR 12-04-2019 X0306 4 2019-12-04 0 0001369568 CATALYST PHARMACEUTICALS, INC. CPRX 0001279473 INGENITO GARY 355 ALHAMBRA CIRCLE, SUITE 1250 CORAL GABLES FL 33134 0 1 0 0 Chief Medical Officer Common stock, par value $0.001 per share 2019-12-04 4 M 0 150000 2.53 A 150000 D Common stock, par value $0.001 per share 2019-12-05 4 S 0 150000 4.821 D 0 D Options to purchase common stock 2.53 2019-12-04 4 M 0 150000 0 A 2022-12-30 Common Stock 150000 886000 D Dr. Ingenito has advised the Company that this sale of shares was to complete the raising of funds required for the purchase of a home by a family member and does not relate to any disagreements with the Company on any matter relating to the Company's operations, policies and practices. Dr. Ingenito remains an officer of the Company. The option was granted on December 30, 2015 and previously vested in two equal annual installments. /s/ Gary Ingenito 2019-12-06